TY - JOUR
T1 - Evaluation of an Interprofessional Training Program to Improve Cancer Drug Therapy Safety
AU - Aebersold, Michelle L.
AU - Kraft, Shawna
AU - Farris, Karen B.
AU - Scherdt, Marylee
AU - Olsen, Mi Kaela
AU - Polovich, Martha
AU - Shelton, Brenda K.
AU - Montgomery, Guy H.
AU - Friese, Christopher R.
N1 - Funding Information:
Supported by the National Cancer Institute (R25CA214227). Additional support provided from the University of Michigan Rogel Cancer Center (P30CA046592). Views presented herein are solely of the authors and do not represent the National Institutes of Health or the National Cancer Institute.
Funding Information:
Supported by the National Cancer Institute (R25CA214227). Additional support provided from the University of Michigan Rogel Cancer Center (P30CA046592). Views presented herein are solely of the authors and do not represent the National Institutes of Health or the National Cancer Institute.
Publisher Copyright:
© 2021 by American Society of Clinical Oncology.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - PURPOSE Drug therapy for cancer is a high-risk, high-volume clinical intervention that requires interprofessional teams. Given the complexity of anticancer drug therapy and safety concerns, an interdisciplinary team developed a novel training program for oncology registered nurses and pharmacists to improve cancer drug safety. METHODS Participants completed preworkshop learning assessments and received access to web-based modules on six topics: hazardous drug handling, drug extravasation, hypersensitivity reaction management, sepsis recognition, immune checkpoint inhibitor toxicities, and oral oncolytic adherence. In a 7-hour workshop, participants applied module content in interactive exercises and high-fidelity simulations. Preworkshop and postworkshop questionnaires assessed changes in knowledge and confidence in each topic. Program satisfaction and changes to clinical practice or policies were assessed 3 months after the workshop. RESULTS Two hundred ninety-two nurses and 82 pharmacists applied to participate, and 103 (35%) and 44 (54%) have participated, respectively. Long-term follow-up data were available on 133 (90%) participants. Change scores in confidence to meet program objectives increased between pre- and postworkshop (range of increase 0.6-0.8, P, .01). Knowledge scores increased significantly between pre- and postworkshop (average improvement of 3.2 points, P, .01). Overall program satisfaction was high (mean 5.0, standard deviation [0.2] on a five-point scale). Seventy-seven (60%) reported that they had made at least one clinical practice or institutional policy change at 3 months. CONCLUSION An interprofessional education program with online modules, in-person interactive sessions, and simulation activities is a promising strategy to deliver cancer drug safety content to practicing oncology clinicians.
AB - PURPOSE Drug therapy for cancer is a high-risk, high-volume clinical intervention that requires interprofessional teams. Given the complexity of anticancer drug therapy and safety concerns, an interdisciplinary team developed a novel training program for oncology registered nurses and pharmacists to improve cancer drug safety. METHODS Participants completed preworkshop learning assessments and received access to web-based modules on six topics: hazardous drug handling, drug extravasation, hypersensitivity reaction management, sepsis recognition, immune checkpoint inhibitor toxicities, and oral oncolytic adherence. In a 7-hour workshop, participants applied module content in interactive exercises and high-fidelity simulations. Preworkshop and postworkshop questionnaires assessed changes in knowledge and confidence in each topic. Program satisfaction and changes to clinical practice or policies were assessed 3 months after the workshop. RESULTS Two hundred ninety-two nurses and 82 pharmacists applied to participate, and 103 (35%) and 44 (54%) have participated, respectively. Long-term follow-up data were available on 133 (90%) participants. Change scores in confidence to meet program objectives increased between pre- and postworkshop (range of increase 0.6-0.8, P, .01). Knowledge scores increased significantly between pre- and postworkshop (average improvement of 3.2 points, P, .01). Overall program satisfaction was high (mean 5.0, standard deviation [0.2] on a five-point scale). Seventy-seven (60%) reported that they had made at least one clinical practice or institutional policy change at 3 months. CONCLUSION An interprofessional education program with online modules, in-person interactive sessions, and simulation activities is a promising strategy to deliver cancer drug safety content to practicing oncology clinicians.
UR - http://www.scopus.com/inward/record.url?scp=85118598515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118598515&partnerID=8YFLogxK
U2 - 10.1200/OP.20.00816
DO - 10.1200/OP.20.00816
M3 - Article
C2 - 33577351
AN - SCOPUS:85118598515
SN - 2688-1527
VL - 17
SP - E1551-E1558
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 10
ER -